Business Wire

PROCURITAS

24.8.2021 09:32:05 CEST | Business Wire | Press release

Share
Procuritas Sells Dantherm Following the Group’s Successful Transformational Growth

Procuritas Capital Investors V (“Procuritas”), the private equity investor focused on investing in and growing Nordic mid-market companies, today announced that it has sold Dantherm Group (“Dantherm”), the leading provider of climate control products and solutions, to German private equity fund, DBAG Fund VIII, advised by Deutsche Beteiligungs AG.

Headquartered in Denmark, Dantherm has more than 60 years’ experience in designing and manufacturing high quality and energy efficient equipment for heating, cooling, drying, cleaning and ventilation for a wide range of portable and installed applications.

After acquiring the business in 2016, Procuritas invested in Dantherm to enable it to expand the geographical presence, to expand the product range and to take a leading market position in its core businesses in Europe.

Alongside the expansion of the business’ sales capabilities, strengthened senior management team and investment in its own manufacturing capacity, Procuritas utilized its extensive value creation expertise and network to partner with the Group to implement an active buy and build strategy. Under Procuritas’ ownership, Dantherm acquired close to 20 entities in its core markets of the UK, Italy, Denmark, Germany, France, Poland, Russia, Switzerland and Spain, realizing considerable integration synergies and significantly expanding the group’s capabilities and scale, resulting in a more than threefold rise in revenues and EBITDA growth of almost 700%.

Dantherm now operates in Norway, Sweden, Denmark, United Kingdom, Germany, Switzerland, Italy, Spain, Poland, Russia, France and China, where its strong brands – Aerial, Aircenter, BioCool, Calorex, Dantherm, Heylo, Master, SET and Sovelor – have well-established market positions. The group’s customers benefit from a comprehensive knowledge base and the experience and expertise from more than three million climate control products and solutions sold worldwide.

Hans Wikse, Partner at Procuritas, commented: “We are delighted to have sold Dantherm to DBAG Fund VIII, advised by Deutsche Beteiligungs AG, having received keen interest from several parties. We think it is a great fit for the company and they will have a great future. Dantherm has been a classic buy and build investment for Procuritas and our strategy was implemented following the methodical process we have undertaken with many other investments over the years.”

Bjarke Brøns, CEO of Dantherm commented: “ Over the past six years we have transformed Dantherm to become a market leading provider of selected climate control solutions. Procuritas has been a great partner to work with and their expertise in transforming companies through acquisition and by institutionalizing the business has been a great support as we have grown the Group. We see continued and extended market opportunities within our business and are excited to continue the development of Dantherm in the future with DBAG.”

Oskar Lindholm-Wu, Partner at Procuritas, commented: “It has been a pleasure to work with the Dantherm team, putting our passion for building strong sustainable businesses through transformational growth to work. Together, we have achieved remarkable growth, transforming the group into the leader in all its core markets across Europe. We wish Dantherm a prosperous future.”

DC Advisory served as M&A advisor, Kromann Reumert as legal advisor and EY as financial due diligence advisor to Procuritas and Dantherm in connection with the transaction.

About Procuritas

Procuritas is a private equity investor, focused on investing in and growing Nordic mid-market companies. With a passion for business, hands-on active ownership approach and more than thirty-year record from a large variety of transactions, it has supported more than 45 companies in accelerating their growth and realizing their true business potential. As owners, Procuritas is characterized by its enthusiasm, commitment, and strong belief that it is an ally in the quest to build strong and sustainable businesses. Read more at www.procuritas.com .

About Dantherm Group

Headquartered in Skive, Denmark, the Dantherm Group is a European leader in portable and installed climate control solutions for a wide range of industries within heating, drying, cooling, cleaning and ventilation. Dantherm has subsidiaries in Norway, Sweden, UK, Germany, Switzerland, Italy, France, Spain, Poland, Russia and China. In 2016 the Dantherm Group was acquired by Procuritas Capital Investors V LP. Read more at www.danthermgroup.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye